American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation (Q38236812)

31 August 2017

American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation (English)

1 reference

31 August 2017

1 reference

1 reference

irritable bowel syndrome

1 reference

1

1 reference

31 August 2017

Paul Moayyedi

2

0 references

Eamonn M M Quigley

9

object named as

Eamonn M M Quigley

1 reference

31 August 2017

Brian E Lacy

3

1 reference

31 August 2017

Anthony J Lembo

4

1 reference

31 August 2017

Yuri A Saito

5

1 reference

31 August 2017

Lawrence R Schiller

6

1 reference

31 August 2017

Edy E Soffer

7

1 reference

31 August 2017

Brennan M R Spiegel

8

1 reference

31 August 2017

Task Force on the Management of Functional Bowel Disorders

10

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

The American Journal of Gastroenterology

31 August 2017

1 reference

31 August 2017

109 Suppl 1

1 reference

31 August 2017

S2-26; quiz S27

1 reference

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis

31 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Impact of persistent constipation on health-related quality of life and mortality in older community-dwelling women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Stool form scale as a useful guide to intestinal transit time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Irritable bowel syndrome: physicians' awareness and patients' experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Systematic review on the management of chronic constipation in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Epidemiology of functional constipation and comparison with constipation-predominant irritable bowel syndrome: the Systematic Investigation of Gastrointestinal Diseases in China (SILC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Towards positive diagnosis of the irritable bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Epidemiologic risks for food allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Perceived food intolerance in subjects with irritable bowel syndrome-- etiology, prevalence and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Abnormal colonic fermentation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A diet low in FODMAPs reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Irritable bowel syndrome: Assessment of psychological disturbance and its influence on the response to fibre supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Psyllium therapy in the irritable bowel syndrome. A double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Wheat fibre and irritable bowel syndrome. A controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Double blind study of ispaghula in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effects of linseeds on the symptoms of irritable bowel syndrome: a pilot randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Postinfectious irritable bowel syndrome--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The microbiota link to irritable bowel syndrome: an emerging story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A mixture ofEscherichia coli(DSM 17252) andEnterococcus faecalis(DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of probiotics on symptoms in korean adults with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The non-effect of pirenzepine in dietary resistant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The Effect of Enteric-Coated, Delayed-Release Peppermint Oil on Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Irritable colon and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized controlled trial of imipramine in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The treatment of irritable bowel syndrome with hypnotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Self-management for women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Preliminary study of a self-administered treatment for irritable bowel syndrome: comparison to a wait list control group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: short- and long-term benefit of relaxation training for irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Brief cognitive-behavioral internet therapy for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome – A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of autogenic training on general improvement in patients with irritable bowel syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Serotonergic modulating drugs for functional gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of wheat bran in treatment of chronic nonorganic constipation. A double-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A combination of fibre-rich rye bread and yoghurt containing Lactobacillus GG improves bowel function in women with self-reported constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Treatment of chronic constipation with lactulose syrup: results of a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Lactulose Syrup Assessed in a Double-Blind Study of Elderly Constipated Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Oral bisacodyl is effective and well-tolerated in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A placebo-controlled trial of prucalopride for severe chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Prucalopride, a systemic enterokinetic, for the treatment of constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Intestinal macrophages display reduced permissiveness to human immunodeficiency virus 1 and decreased surface CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Efficacy of linaclotide for patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Two randomized trials of linaclotide for chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Efficacy and safety of lubiprostone in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Pelvic floor: anatomy and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Recognition and management of nonrelaxing pelvic floor dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized controlled trial of anorectal biofeedback for constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Behavioural treatment of the dyssynergic defecation in chronically constipated elderly patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Biofeedback retraining in patients with functional constipation and paradoxical puborectalis contraction: comparison of anal manometry and sphincter electromyography for feedback

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Comparing the efficacy of biofeedback and balloon-assisted training in the treatment of dyssynergic defecation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Fermented milk containing Lactobacillus casei strain Shirota reduces incidence of hard or lumpy stools in healthy population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2014.187

21 January 2018

Identifiers

DOI

10.1038/AJG.2014.187

1 reference

31 August 2017

1 reference